ライフサイエンスコーパス: patients with or without

1 yocardial ischemic events were consistent in patients with or without a baseline history of MI or cor

2 were low and not significantly different in patients with or without a DUODX.

3 When comparisons were made between patients with or without a history of kidney failure, th

4 h motor and behavioral symptoms occurring in patients with or without a history of psychiatric illnes

5 4.00]) and in a broader population including patients with or without a history of stroke (RR, 1.40 [

6 ted with a lower risk of POE and is safe for patients with or without a perioperative capsular ruptur

7 termine whether the association differed for patients with or without a recent MI.

8 For patients with or without a related donor, respective 5-y

9 asis of pregnancy [ICP]) were similar in the patients with or without ABCB4 gene sequence variation.

10 In contrast, CR rates were similar in patients with or without abnormal karyotypes.

11 choalveolar lavage fibrocyte percentage from patients with or without acute lung injury and acute res

12 rocytes in bronchoalveolar lavage fluid from patients with or without acute lung injury and acute res

13 ated with improvements in quality of life in patients with or without advanced liver disease.

14 amples from APACHE II-matched critically ill patients with or without advancing azotemia (n = 10 in e

15 There were no cases of mortality in patients with or without AKI.

16 Clinicians cannot accurately differentiate patients with or without alcoholic hepatitis without liv

17 ay be a marker of genetic susceptibility for patients with or without AMD.

18 s, however, were not increased in chest pain patients with or without AMI.

19 nce of postextubation stridor was similar in patients with or without an airleak at >20 mm Hg (50% vs

20 h AIDS (39% in 1999 to 16% in 2013), both in patients with or without an infection.

21 Troponin-positive patients with or without angiographic CAD had higher CRP

22 nondiabetic and diabetic (type 2 and type 1) patients with or without angiographically documented CAD

23 atch or 1 year Kaplan-Meier survival between patients with or without anti-HLA antibodies.

24 Sixty eyes of 32 patients with or without any ocular chorioretinal diseas

25 -state after approximately 12 weeks, both in patients with or without AR.

26 Postoperative outcomes were compared among patients with or without ARI or ARF.

27 eal differential gene expression patterns in patients with or without arteriolar hyalinization.

28 mentation of the ACH response was similar in patients with or without atherosclerosis.

29 ing gray matter (GM) volume of schizophrenic patients with or without auditory verbal hallucinations

30 ed pupil physiology to successfully classify patients with or without autism.

31 Posttransplant sera of patients with or without AVR were tested for the presenc

32 These differences were observed for patients with or without baseline BCR-ABL1 mutations and

33 toms significantly impacted RFS (P > .10) in patients with or without baseline symptoms.

34 n important salvage option for TKI-resistant patients with or without BCR-ABL1 mutations.

35 TB were inaccurate for correctly classifying patients with or without bloodstream MTB infection.

36 H, and PPARgamma agonists may reverse PAH in patients with or without BMP-RII dysfunction.

37 ge area of TRPV1 expression in neuromas from patients with or without burning dysaesthesia.

38 Patients with or without carcinoma had similar clinical

39 DGL procedure in identification of pediatric patients with or without celiac disease, without biopsy.

40 although no difference was observed between patients with or without cGVHD (P = .13).

41 Four-month clinical outcomes were similar in patients with or without chest pain relief with nitrogly

42 Adjusted MR ratios (MRRs) between patients with or without cirrhosis and their comparison

43 , and 6 or 8 weeks for treatment-experienced patients with or without cirrhosis.

44 ir + peginterferon + ribavirin, 12 weeks for patients with or without cirrhosis.

45 nces in rates of SVR12 were observed between patients with or without cirrhosis.

46 s with higher risk for HF, MI, and PAD among patients with or without CKD.

47 latter pathological changes may be found in patients with or without clinical evidence of MND.

48 The combination was safe and effective in patients with or without compensated cirrhosis.

49 rtality for aortic and/or mitral heart valve patients with or without concomitant CABG.

50 sed to identify patients with nonvalvular AF patients with or without concomitant HF.

51 d in vitro from carefully defined cohorts of patients with or without concomitant hypertension and th

52 aphy and their association with mortality in patients with or without coronary artery disease (CAD).

53 cardiovascular mortality occurs in diabetic patients with or without coronary artery disease and is

54 istent in all age groups, and was similar in patients with or without coronary artery disease, hypert

55 Similarly, in subsets of patients with or without coronary artery disease, scar i

56 larly confers increased risk of mortality in patients with or without coronary artery disease.

57 wer risks of death and hospitalization among patients with or without coronary heart disease.

58 We sequenced c-Cbl, Cbl-b, and Cbl-c in patients with or without corresponding UPD or deletions

59 blood (WB) and plasma (Pl) was evaluated in patients with or without CP by end-point-limiting diluti

60 in survival 1 month after treatment between patients with or without cytochrome b mutations (P=.14).

61 Outcomes of patients with or without detectable anti-PLA2R antibodie

62 vival associated with TAC+MMF and CYA+MMF in patients with or without DGF or early acute rejection.

63 it (SICU)/medical intensive care unit (MICU) patients with or without diabetes mellitus (Grade: stron

64 rapy to normalize blood glucose in SICU/MICU patients with or without diabetes mellitus (Grade: stron

65 targets and health outcomes in hospitalized patients with or without diabetes mellitus.

66 , men and women, smokers and nonsmokers, and patients with or without diabetes or hypertension.

67 elderly as well as younger patients, and to patients with or without diabetes or metabolic syndrome.

68 ssociated with an increased risk of death in patients with or without diabetes.

69 e use of ACE inhibitors and beta-blockers in patients with or without diabetes.

70 nd accelerated vasculopathy in renal failure patients with or without diabetes.

71 ation of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.

72 rapy for MRD, and the 2-year CIR and LFS for patients with or without DLI was 24% vs 87% (P5.001) and

73 h continued thienopyridine was similar among patients with or without DM (interaction P=0.61).

74 f primary leukemic and non-leukemic cells in patients with or without DNMT3A(R882) mutations.

75 tifibatide treatment effect differed between patients with or without early PCI (P for interaction=0.

76 ignificant differences were observed between patients with or without early rejection episodes.

77 , neurologic, and psychiatric features of CD patients with or without effective AM.

78 rative and postoperative serum creatinine in patients with or without embolization was 0.2 (0.05) ver

79 The mean operation time in patients with or without embolization was 5.2 (1.2) vers

80 The mean (SD) estimated blood loss in patients with or without embolization was 600 (173) vers

81 HIV-1 gene products in brain tissue of AIDS patients with or without encephalitis and HIV-seronegati

82 Consistent results were seen in patients with or without established CVD.

83 urations, for different comparators, and for patients with or without established vascular disease.

84 ypes identified were found nearly equally in patients with or without evidence of dissemination.

85 was no difference in characteristics between patients with or without F317L mutations, or with no mut

86 could lower Abeta, especially Abeta42, in AD patients with or without familial mutations.

87 In asymptomatic or symptomatic patients with or without FMR, PH is a critical marker fo

88 ivity in mild IBS patients and in severe IBS patients with or without FMS.

89 PD patients with or without GBA1 mutations also exhibit low

90 proteinuria allows stratification of risk in patients with or without glomerular pathology.

91 d was found for hemorrhagic complications in patients with or without glycoprotein IIb/IIIa inhibitor

92 Banff pathology characteristics for ABMR patients with or without graft loss did not differ.

93 rphism was associated with graft survival in patients with or without HCV undergoing LT.

94 BNP power in distinguishing patients with or without heart failure symptoms was less

95 ReQuest scores significantly decreased in patients with or without heartburn and in those with sym

96 prevention in 8101 hospitalized acutely ill patients with or without HF.

97 hemistry of GluR1 were used to determine, in patients with or without hippocampal sclerosis (HS), if

98 was not significantly different between LBBB patients with or without history of IAT (HR: 0.50, p = 0

99 using sporadic cases of PCP in nontransplant patients with or without HIV infection.

100 n-10 (IL-10) mRNA expression in tuberculosis patients with or without human immunodeficiency virus in

101 expression in lymph nodes from tuberculosis patients with or without human immunodeficiency virus in

102 ument that plasma from all of four acute TTP patients, with or without human immunodeficiency virus i

103 while ACE expression showed no difference in patients with or without hypertension, upregulation of c

104 ed significantly after 1 day of treatment in patients with or without hyperuricemia at diagnosis (P =

105 as performed and gene expression patterns in patients with or without inflammation compared.

106 Intestinal tissue samples from patients with or without inflammatory bowel disease (con

107 otential therapeutic approach for hemophilia patients with or without inhibitory antibodies to human

108 mortality is not significantly different for patients with or without intrathoracic leaks (3.3% versu

109 fter stroke onset (84 acute ischaemic stroke patients with or without intravenous tPA treatment, comp

110 ) from human immunodeficiency virus-positive patients with or without Kaposi's sarcoma.

111 relapse were not significantly different for patients with or without KIT mutations.

112 Obese or overweight patients with or without known CAD who had normal MPS we

113 lower adjusted risks of adverse outcomes in patients with or without known coronary heart disease.

114 elates were studied and outcomes assessed in patients with or without Kussmaul physiology after a mea

115 ents with active pulmonary TB and in control patients with or without latent infection.

116 ptomic analyses were done in plasma RNA from patients with or without left ventricular remodeling aft

117 Patients with or without linear lesions did not differ s

118 roves gut barrier function and whether obese patients with or without liver steatosis differ in this

119 Patients with or without Lofgren syndrome had similar fr

120 M, occurring with different frequency in HCM patients with or without LV hypertrophy.

121 (MD) with 95% CIs of each aspect of HRQL in patients with or without major postoperative complicatio

122 nts, cardiovascular events, and death in CHB patients with or without metabolic syndrome.

123 Between 1988 and 1992, patients with or without metastatic disease were randomi

124 SRS was equally useful in patients with or without metastatic liver disease.

125 age and statin therapy on AS progression in patients with or without MetS.

126 rence in graft survival was observed between patients with or without microcirculation inflammation i

127 Patients with or without mutations had similar rates of

128 cytogenetic response rates were similar for patients with or without mutations.

129 uate the relative risk of primary outcome in patients with or without NA treatment.

130 In this study, the presence of FLCs in CRS patients with or without nasal polyps (CRSw/sNP) was inv

131 us levels between healthy subjects and obese patients (with or without NASH), and relatively fewer di

132 atocyte growth factor differentiated between patients with or without neurological complications.

133 fficacy; rates of SVR12 were 70% and 98% for patients with or without NS5A polymorphisms, respectivel

134 s are already increased in pretransplant CHF patients with or without occlusive coronary artery disea

135 was no difference in event-free survival in patients with or without ON.

136 ately predicts acute kidney injury in septic patients with or without other organ failures.

137 as no difference in overall survival between patients with or without p16 methylation.

138 the differential plasma proteins in 272 CHD patients with or without PAH.

139 e in the troponin-T values did not differ in patients with or without PCI or in those with a diagnosi

140 Hazard ratios for DFS comparing patients with or without pCR were lowest when defined as

141 all treatment groups and were comparable in patients with or without PED at baseline treated with ra

142 y, comparing gingival biopsies obtained from patients with or without periodontal disease.

143 Examination of plasma from patients with or without PGD revealed that higher levels

144 Part 1 included patients with or without PIK3CA mutations, whereas part

145 ti-JCV antibody index values, separately for patients with or without PML.

146 in only a few kidney samples of HIV-positive patients, with or without PML, and rarely in the bones o

147 classes: class 1 (n = 49, 37.7%) represented patients with or without positive RT-PCR but no immunolo

148 llosis); class 3 (n = 19, 14.6%) represented patients with or without positive RT-PCR, elevated A fum

149 seline and operative characteristics between patients with or without PPM.

150 ference in progression-free survival between patients with or without predicted NK alloreactivity (42

151 Patients with or without preoperative CHF exhibited simi

152 (or alcohol septal ablation), 92% and 95% of patients with or without preoperative pulmonary hyperten

153 There was no difference in OS between patients with or without preoperative SCPN (16.1 vs 19.1

154 ut not in PTPC, time on therapy, or rPFS for patients with or without pretherapy AR-V7-positive CTCs

155 Rates of remission were similar between patients with or without previous immunosuppressive trea

156 nted escalation beyond the starting dose for patients with or without previous pelvic radiotherapy.

157 ocedure creatine kinase (CK)-MB elevation in patients with or without prior beta-blocker therapy and

158 Patients with or without prior chemotherapy received nit

159 es with LY353381 to evaluate the efficacy in patients with or without prior exposure to tamoxifen and

160 ES occurred with similar frequency in patients with or without prior myectomy (P=0.84).

161 ion of dual antiplatelet therapy duration in patients with or without prior myocardial infarction (MI

162 A and B) compared data from stable cirrhotic patients with or without prior OHE.

163 One-year survival rates for patients with or without prior therapy for metastatic di

164 ng PVR in humans, we subjected vitreous from patients with or without PVR to a similar series of anal

165 termediate 90-day survival rates compared to patients with or without PVT at both listing and LT.

166 uld be 64 Gy or slightly higher and that, in patients with or without radiation therapy, there is no

167 percutaneous coronary intervention (PCI) in patients with or without raised baseline hs-TnT levels i

168 in-3 (PTX3) analyses of sera from 87 leprosy patients with or without reactions were conducted via en

169 Type 2 diabetic patients, with or without retinopathy, had reduced MPOD

170 scores, and renal function were analyzed in patients with or without RRT after CF-LVAD implantation.

171 tion on human NK cells in a cohort of 28 MPN patients with or without ruxolitinib treatment and 24 he

172 d transplant specimens from 46 genotyped HCM patients with or without sarcomere gene mutations and 10

173 derlying segmental perfusion defects; 43% of patients with or without segmental perfusion defects dem

174 f tissue and that it can accurately identify patients with or without sequestered parasites in cerebr

175 ot discriminate between the risk of death in patients with or without significant CAD, and the indepe

176 value of 90% correctly categorized 28 of 30 patients with or without significant pulmonary function

177 A total of 8,404 patients, with or without ST-segment elevation acute cor

178 surgical outcome parameters were similar in patients with or without statins, although statin users

179 dochotomies, complications and mortality) in patients with or without statins.

180 serum samples from 8 HCV genotype 3-infected patients with or without steatosis, we sequenced the HCV

181 Parathyroidectomy in patients with or without symptoms led to normalization o

182 d and strain-derived dyssynchrony indexes in patients with or without systolic dysfunction and left b

183 riate when preliminary evidence suggest that patients with or without that marker profile do not bene

184 intrinsic connectivity network integrity in patients with or without the C9orf72 expansion.

185 s no difference in sensitivity of cells from patients with or without the del(17p13.1) abnormality.

186 rstood, and the T cell-reactivity pattern in patients with or without the HLA-B*58:01 allele is not k

187 tient health-care visits (non-Hispanic white patients with or without the rare Ile 164 allele, 2.6 [S

188 [2.1] visits, p<0.0001; and African American patients with or without the rare insertion, 3.7 [4.6] v

189 trigger, recurrence rates did not differ in patients with or without thrombophilia (1.34 [0.73-2.46]

190 scernible differences in CD8+ recovery among patients with or without thymic enlargement, whereas CD4

191 th, heart failure, or arrhythmic events, for patients with or without TTNtv (hazard ratio adjusted fo

192 nse in atherosclerotic carotid arteries from patients with or without type 2 diabetes, and carotid pl

193 (n=6) and from nonischemic failing hearts of patients with or without type 2 diabetes.

194 y rate was 7.8% (n=87) versus 2.9% (n=33) in patients with or without type 2 DM (P<0.001), respective

195 ons or rare variants in SCN5A may predispose patients with or without underlying heart disease to AF.

196 rence in OCT characteristics of ONHD between patients with or without VF defects.

197 aracteristics are significantly different in patients with or without VF defects.

198 tcomes, as well as net clinical outcomes, in patients with or without VHD treated with edoxaban or wa

199 de overall efficacy and safety similar in AF patients with or without VHD.